Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (121-130 of 194) with videos related to

Pageof 20
Sort By:
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|April 13, 2012
Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou, Qing Zhang, Owen Stephens, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
Blood|October 20, 2007
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi, Guido J Tricot, Tarun K Garg, et al.
British Journal of Haematology|February 13, 2001
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myelomaJ R Sawyer, J L Lukacs, E L Thomas, et al.
Blood Cancer Journal|January 6, 2026
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myelomaToshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Pageof 20

Showing results (121-130 of 194) with videos related to

Sort By:
Pageof 20
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|April 13, 2012
Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou, Qing Zhang, Owen Stephens, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Plos One|February 2, 2013
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone, Emily Woods, Susann M Szmania, et al.
Blood|October 20, 2007
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi, Guido J Tricot, Tarun K Garg, et al.
British Journal of Haematology|February 13, 2001
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myelomaJ R Sawyer, J L Lukacs, E L Thomas, et al.
Blood Cancer Journal|January 6, 2026
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myelomaToshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Pageof 20